Exanta (ximelagatran) won't be approved and won't be replacing warfarin any time soon

The new anticoagulant Exanta (ximelagatran) won't be approved and won't be replacing warfarin any time soon.

The problem is liver toxicity.

It was hoped that Exanta would be safer and easier to use.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote